Interestingly, all three compounds significantly improved locomotor function of HD larvae at five different ten-fold diluted nanomolar concentrations, suggesting that EAAT2 activators have the potential to rescuing locomotor behavior in vivo over a wide range of doses. This evidence concerns the gene SLC1A2 and Huntington disease.